{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:54:59Z","timestamp":1781560499977,"version":"3.54.5"},"reference-count":24,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T00:00:00Z","timestamp":1465171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Palliative Medicine"],"published-print":{"date-parts":[[2016,11,1]]},"DOI":"10.1089\/jpm.2016.0220","type":"journal-article","created":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T15:42:10Z","timestamp":1465227730000},"page":"1224-1225","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Olanzapine for Nausea, Delirium, Anxiety, Insomnia, and Cachexia #315"],"prefix":"10.1177","volume":"19","author":[{"given":"Maria","family":"Felton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Pruskowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,6,6]]},"reference":[{"key":"e_1_3_1_2_2","first-page":"199","article-title":"Retrospective study of olanzapine in depressive and anxious states in primary care","volume":"6","author":"Jackson WC","year":"2004","unstructured":"Jackson WC, , Manning JS, , Connor PD, et al. Retrospective study of olanzapine in depressive and anxious states in primary care. Prim Care Companion J Clin Psychiatry, 2004; 6:199\u2013202.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"e_1_3_1_3_2","article-title":"Rational use of second-generation antipsychotic for the treatment of ICU delirium: A neuropharmacological approach","author":"Mo Y","year":"2015","unstructured":"Mo Y, , Yam F. Rational use of second-generation antipsychotic for the treatment of ICU delirium: A neuropharmacological approach. J Pharm Pract, 2015; pii:0897190015585763.","journal-title":"J Pharm Pract"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200207000-00004"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937030-00001"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(95)00197-L"},{"key":"e_1_3_1_7_2","first-page":"36","article-title":"Which psychotropics carry the greatest risk of QTc prolongation?","volume":"11","author":"Washington NB","year":"2012","unstructured":"Washington NB, , Brahm NC, , Kissack J. Which psychotropics carry the greatest risk of QTc prolongation?. Curr Psychiatry, 2012; 11:36\u201339.","journal-title":"Curr Psychiatry"},{"issue":"2","key":"e_1_3_1_8_2","first-page":"3","article-title":"Atypical antipsychotics: Sleep, sedation, and efficacy","volume":"6","author":"Miller DD","year":"2004","unstructured":"Miller DD. Atypical antipsychotics: Sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry, 2004; 6(Suppl 2):3\u20137.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4530(02)00114-2"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/1049909112441241"},{"key":"e_1_3_1_11_2","first-page":"188","article-title":"Prescription of olanzapine in children and adolescent psychiatric patients","volume":"33","author":"Fremaux T","year":"2007","unstructured":"Fremaux T, , Reymann JM, , Chevreuil C, et al. Prescription of olanzapine in children and adolescent psychiatric patients. Encephale, 2007; 33:188\u2013196.","journal-title":"Encephale"},{"key":"e_1_3_1_12_2","unstructured":"Product Information: ZYPREXA(R) oral tablets olanzapine oral tablets. Lilly USA LLC (per FDA) Indianapolis IN 2013."},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S13109"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.10.023"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00391-3"},{"key":"e_1_3_1_16_2","first-page":"1143","article-title":"Olanzapine for chemotherapy-induced nausea and vomiting: Asystematic review","volume":"22","author":"Hocking CM","year":"2014","unstructured":"Hocking CM, , Kichenadasse G. Olanzapine for chemotherapy-induced nausea and vomiting: Asystematic review. Support Care Cancer, 2014; 22:1143\u20131151.","journal-title":"Support Care Cancer"},{"key":"e_1_3_1_17_2","first-page":"1655","article-title":"The use of olanzapine versus metoclopramide for the treatment of breakthrough nausea and vomiting in patients receiving highly emetogenic chemotherapy","volume":"21","author":"Navari RM","year":"2013","unstructured":"Navari RM, , Nagy CK, , Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer, 2013; 21:1655\u20131663.","journal-title":"Support Care Cancer"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-015-0550-8"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2010.02.017"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.43.3.175"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.07.005"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0407"},{"key":"e_1_3_1_23_2","first-page":"951","article-title":"Treatment of cancer-related anorexia with olanzapine and megestrol acetate: A randomized trial","volume":"18","author":"Navari RM","year":"2010","unstructured":"Navari RM, , Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: A randomized trial. Support Care Cancer, 2010; 18:951\u2013956.","journal-title":"Support Care Cancer"},{"key":"e_1_3_1_24_2","first-page":"2649","article-title":"Olanzapine for cachexia in patients with advance cancer: An exploratory study of effects on weight and metabolic cytokines","volume":"23","author":"Naing A","year":"2015","unstructured":"Naing A, , Dalal S, , Abdelrahim M, et al. Olanzapine for cachexia in patients with advance cancer: An exploratory study of effects on weight and metabolic cytokines. Support Care Cancer, 2015; 23:2649\u20132654.","journal-title":"Support Care Cancer"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S27344"}],"container-title":["Journal of Palliative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jpm.2016.0220","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jpm.2016.0220","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jpm.2016.0220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:39:09Z","timestamp":1781559549000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jpm.2016.0220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,6]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11,1]]}},"alternative-id":["10.1089\/jpm.2016.0220"],"URL":"https:\/\/doi.org\/10.1089\/jpm.2016.0220","relation":{},"ISSN":["1096-6218","1557-7740"],"issn-type":[{"value":"1096-6218","type":"print"},{"value":"1557-7740","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,6]]}}}